I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Image_1_High-throughput drug screening identifies fluoxetin..:
Lei Chen
;
Yiyi Ji
;
Ang Li
...
doi:10.3389/fonc.2023.1085569.s001. , 2023
Link:
https://doi.org/10.3389/fonc.2023.1085569.s001
RT Journal T1
Image_1_High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer.tif
UL https://suche.suub.uni-bremen.de/peid=base-ftfrontimediafig:oai:figshare.com:article_22263178&Exemplar=1&LAN=DE A1 Lei Chen A1 Yiyi Ji A1 Ang Li A1 Bo Liu A1 Kai Shen A1 Ruopeng Su A1 Zehua Ma A1 Weiwei Zhang A1 Qi Wang A1 Yinjie Zhu A1 Wei Xue YR 2023 K1 Cancer K1 Cancer Cell Biology K1 Cancer Diagnosis K1 Cancer Genetics K1 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) K1 Chemotherapy K1 Haematological Tumours K1 Molecular Targets K1 Radiation Therapy K1 Solid Tumours K1 Oncology and Carcinogenesis not elsewhere classified K1 NEPC K1 fluoxetine K1 prostate cancer K1 drug repurposing K1 high-throughput drug screening JF doi:10.3389/fonc.2023.1085569.s001 LK http://dx.doi.org/https://doi.org/10.3389/fonc.2023.1085569.s001 DO https://doi.org/10.3389/fonc.2023.1085569.s001 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)